{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T21:01:43Z","timestamp":1783026103359,"version":"3.54.6"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Private Philanthropic Grant provided by Dr Jeff Wolinksi"},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1129815"],"award-info":[{"award-number":["1129815"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s40263-018-0506-8","type":"journal-article","created":{"date-parts":[[2018,3,16]],"date-time":"2018-03-16T09:09:23Z","timestamp":1521191363000},"page":"179-187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial"],"prefix":"10.1007","volume":"32","clinical-trial-number":[{"clinical-trial-number":"nct02097706","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3875-5623","authenticated-orcid":false,"given":"Jayashri","family":"Kulkarni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul-Rahman","family":"Hudaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emorfia","family":"Gavrilidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raelene","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinta","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gurvich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,16]]},"reference":[{"issue":"9759","key":"506_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(10)61422-5","volume":"377","author":"F Leichsenring","year":"2011","unstructured":"Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet (London, England). 2011;377(9759):74\u201384.","journal-title":"Lancet (London, England)."},{"key":"506_CR2","volume-title":"Clinical practice guideline for the management of borderline personality disorder","author":"National Health and Medical Research Council","year":"2012","unstructured":"National Health and Medical Research Council. Clinical practice guideline for the management of borderline personality disorder. Melbourne: National Health and Medical Research Council; 2012."},{"issue":"1","key":"506_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1745-6215-15-281","volume":"15","author":"LM van den Bosch","year":"2014","unstructured":"van den Bosch LM, Sinnaeve R, Hakkaart-van Roijen L, van Furth EF. Efficacy and cost-effectiveness of an experimental short-term inpatient dialectical behavior therapy (DBT) program: study protocol for a randomized controlled trial. Trials. 2014;15(1):1\u20139.","journal-title":"Trials."},{"issue":"5","key":"506_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1600-0447.2010.01652.x","volume":"123","author":"K Barnicot","year":"2011","unstructured":"Barnicot K, Katsakou C, Marougka S, Priebe S. Treatment completion in psychotherapy for borderline personality disorder\u2014a systematic review and meta-analysis. Acta Psychiatrica Scandinavica. 2011;123(5):327\u201338.","journal-title":"Acta Psychiatrica Scandinavica."},{"issue":"8","key":"506_CR5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1748-5908-8-120","volume":"8","author":"RR Owen","year":"2013","unstructured":"Owen RR, Drummond KL, Viverito KM, Marchant K, Pope SK, Smith JL, et al. Monitoring and managing metabolic effects of antipsychotics: a cluster randomized trial of an intervention combining evidence-based quality improvement and external facilitation. Implement Sci IS. 2013;8(8):120.","journal-title":"Implement Sci IS."},{"key":"506_CR6","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2017-0065","author":"O Abosi","year":"2018","unstructured":"Abosi O, Lopes S, Schmitz S, Fiedorowicz JG. Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig. 2018. https:\/\/doi.org\/10.1515\/hmbci-2017-0065.","journal-title":"Horm Mol Biol Clin Investig."},{"key":"506_CR7","unstructured":"Commonwealth of Australia. Clinical practice guideline for the management of borderline personality disorder. In: Council NHaMR, editor. Canberra: NHMRC; 2012."},{"issue":"1","key":"506_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1192\/bjp.bp.108.062984","volume":"196","author":"K Lieb","year":"2010","unstructured":"Lieb K, Vollm B, Rucker G, Timmer A, Stoffers JM. Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. Br J Psychiatry J Ment Sci. 2010;196(1):4\u201312.","journal-title":"Br J Psychiatry J Ment Sci."},{"issue":"2","key":"506_CR9","first-page":"103","volume":"32","author":"B Grosjean","year":"2007","unstructured":"Grosjean B, Tsai GE. NMDA neurotransmission as a critical mediator of borderline personality disorder. J Psychiatry Neurosci. 2007;32(2):103.","journal-title":"J Psychiatry Neurosci."},{"issue":"2","key":"506_CR10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1521\/pedi.18.2.193.32777","volume":"18","author":"CL Battle","year":"2004","unstructured":"Battle CL, Shea MT, Johnson DM, Yen S, Zlotnick C, Zanarini MC, et al. Childhood maltreatment associated with adult personality disorders: findings from a Collaborative Longitudinal Personality Disorders Study. J Personal Disord. 2004;18(2):193\u2013211.","journal-title":"J Personal Disord."},{"key":"506_CR11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/21674086.1938.11925367","volume":"7","author":"A Stern","year":"1938","unstructured":"Stern A. Psychoanalytic investigation and therapy in the borderline group of neuroses. Psychoanal Q. 1938;7:467\u201389.","journal-title":"Psychoanal Q"},{"issue":"1","key":"506_CR12","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0193-953X(05)70146-5","volume":"23","author":"P Fonagy","year":"2000","unstructured":"Fonagy P, Target M, Gergely G. Attachment and borderline personality disorder: a theory and some evidence. Psychiatr Clin N Am. 2000;23(1):103\u201322.","journal-title":"Psychiatr Clin N Am."},{"issue":"8","key":"506_CR13","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1176\/ajp.154.8.1101","volume":"154","author":"MC Zanarini","year":"1997","unstructured":"Zanarini MC, Williams AA, Lewis RE, Reich RB. Reported pathological childhood experiences associated with the development of borderline personality disorder. Am J Psychiatry. 1997;154(8):1101.","journal-title":"Am J Psychiatry."},{"issue":"1","key":"506_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nrn3138","volume":"13","author":"M Popoli","year":"2012","unstructured":"Popoli M, Yan Z, McEwen BS, Sanacora G. The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci. 2012;13(1):22\u201337.","journal-title":"Nat Rev Neurosci."},{"issue":"2","key":"506_CR15","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/nrd1958","volume":"5","author":"SA Lipton","year":"2006","unstructured":"Lipton SA. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond. Nat Rev Drug Discov. 2006;5(2):160\u201370.","journal-title":"Nat Rev Drug Discov."},{"issue":"12","key":"506_CR16","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1038\/nm1209-1355","volume":"15","author":"AR La Spada","year":"2009","unstructured":"La Spada AR. Memantine strikes the perfect balance. Nat Med. 2009;15(12):1355\u20136.","journal-title":"Nat Med."},{"key":"506_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1001\/archpsyc.57.10.925","volume":"57","author":"RM Sapolsky","year":"2000","unstructured":"Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry. 2000;57:925\u201335.","journal-title":"Arch Gen Psychiatry."},{"key":"506_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/archpsyc.57.12.1115","volume":"57","author":"MHJ Driessen","year":"2000","unstructured":"Driessen MHJ, Stahl K, et al. Magnetic resonance imaging volumes of the hippocampus and the amygdala in women with borderline personality disorder and early traumatization. Arch Gen Psychiatry. 2000;57:1115\u201322.","journal-title":"Arch Gen Psychiatry"},{"key":"506_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-055-3","volume-title":"The glutamate receptors","author":"RW Gereau","year":"2008","unstructured":"Gereau RW, Swanson G. The glutamate receptors. Berlin: Springer Science and Business Media; 2008."},{"issue":"2","key":"506_CR20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ceca.2009.12.009","volume":"47","author":"T Nakamura","year":"2010","unstructured":"Nakamura T, Lipton SA. Preventing Ca2+-mediated nitrosative stress in neurodegenerative diseases: possible pharmacological strategies. Cell Calcium. 2010;47(2):190\u20137.","journal-title":"Cell Calcium."},{"issue":"11","key":"506_CR21","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/sj.mp.4001551","volume":"9","author":"DC Javitt","year":"2004","unstructured":"Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9(11):984\u201397.","journal-title":"Mol Psychiatry."},{"issue":"6","key":"506_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1364-6613(00)01483-2","volume":"4","author":"G Bush","year":"2000","unstructured":"Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cognit Sci. 2000;4(6):215\u201322.","journal-title":"Trends Cognit Sci."},{"issue":"9","key":"506_CR23","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/archgenpsychiatry.2010.93","volume":"67","author":"M Hoerst","year":"2010","unstructured":"Hoerst M, Weber-Fahr W, Tunc-Skarka N, et al. Correlation of glutamate levels in the anterior cingulate cortex with self-reported impulsivity in patients with borderline personality disorder and healthy controls. Arch Gen Psychiatry. 2010;67(9):946\u201354.","journal-title":"Arch Gen Psychiatry."},{"issue":"11","key":"506_CR24","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.4088\/JCP.v66n1121d","volume":"66","author":"C Pittenger","year":"2005","unstructured":"Pittenger C, Krystal JH, Coric V. Initial evidence of the beneficial effects of glutamate-modulating agents in the treatment of self-injurious behavior associated with borderline personality disorder. J Clin Psychiatry. 2005;66(11):1492.","journal-title":"J Clin Psychiatry."},{"issue":"1","key":"506_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.bbr.2007.12.001","volume":"189","author":"AM Muehlmann","year":"2008","unstructured":"Muehlmann AM, Devine DP. Glutamate-mediated neuroplasticity in an animal model of self-injurious behaviour. Behav Brain Res. 2008;189(1):32\u201340.","journal-title":"Behav Brain Res."},{"issue":"8","key":"506_CR26","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","volume":"63","author":"CA Zarate Jr","year":"2006","unstructured":"Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856\u201364.","journal-title":"Arch Gen Psychiatry."},{"issue":"1","key":"506_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/157015908783769671","volume":"6","author":"G Rammes","year":"2008","unstructured":"Rammes G, Danysz W, Parsons CG. Pharmacodynamics of memantine. Curr Neuropharmacol. 2008;6(1):55\u201378.","journal-title":"Curr Neuropharmacol."},{"issue":"5","key":"506_CR28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.neuropharm.2009.01.012","volume":"56","author":"KE Gilling","year":"2009","unstructured":"Gilling KE, Jatzke C, Hechenberger M, Parsons CG. Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-d-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1\/GluN2A) receptors. Neuropharmacology. 2009;56(5):866\u201375.","journal-title":"Neuropharmacology."},{"issue":"3","key":"506_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1527-3458.2003.tb00254.x","volume":"9","author":"MA Rogawski","year":"2003","unstructured":"Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer\u2019s disease. CNS Drug Rev. 2003;9(3):275\u2013308.","journal-title":"CNS Drug Rev."},{"issue":"1","key":"506_CR30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2011.09.040","volume":"136","author":"A Koukopoulos","year":"2012","unstructured":"Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord. 2012;136(1):163\u20136.","journal-title":"J Affect Disord."},{"issue":"40","key":"506_CR31","doi-asserted-by":"publisher","first-page":"9686","DOI":"10.1523\/JNEUROSCI.1173-17.2017","volume":"37","author":"NG Glasgow","year":"2017","unstructured":"Glasgow NG, Povysheva NV, Azofeifa AM, Johnson JW. Memantine and ketamine differentially alter NMDA receptor desensitization. J Neurosci Off J Soc Neurosci. 2017;37(40):9686\u2013704. https:\/\/doi.org\/10.1523\/JNEUROSCI.1173-17.2017.","journal-title":"J Neurosci Off J Soc Neurosci."},{"issue":"2","key":"506_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12017-015-8343-0","volume":"17","author":"SN Amin","year":"2015","unstructured":"Amin SN, El-Aidi AA, Ali MM, Attia YM, Rashed LA. Modification of hippocampal markers of synaptic plasticity by memantine in animal models of acute and repeated restraint stress. Neuromol Med. 2015;17(2):121\u201336.","journal-title":"Neuromol Med."},{"issue":"2","key":"506_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1521\/psyc.2007.70.2.167","volume":"70","author":"MA Battista","year":"2007","unstructured":"Battista MA, Hierholzer R, Khouzam HR, Barlow A, O\u2019Toole S. Pilot trial of memantine in the treatment of posttraumatic stress disorder. Psychiatry. 2007;70(2):167\u201374.","journal-title":"Psychiatry."},{"issue":"4","key":"506_CR34","doi-asserted-by":"publisher","first-page":"e0123289","DOI":"10.1371\/journal.pone.0123289","volume":"10","author":"S Matsunaga","year":"2015","unstructured":"Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer\u2019s disease: a systematic review and meta-analysis. PloS One. 2015;10(4):e0123289.","journal-title":"PloS One."},{"key":"506_CR35","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.2147\/NDT.S142839","volume":"13","author":"T Kishi","year":"2017","unstructured":"Kishi T, Matsunaga S, Iwata N. The effects of memantine on behavioral disturbances in patients with Alzheimer\u2019s disease: a meta-analysis. Neuropsychiatr Dis Treat. 2017;13:1909\u201328.","journal-title":"Neuropsychiatr Dis Treat."},{"issue":"3","key":"506_CR36","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1521\/pedi.17.3.233.22147","volume":"17","author":"MC Zanarini","year":"2003","unstructured":"Zanarini MC. Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Personal Disord. 2003;17(3):233\u201342.","journal-title":"J Personal Disord."},{"key":"506_CR37","unstructured":"West SG, Finch JF, Curran PJ. Structural equation models with non normal variables: problems and remedies. In: Hoyle RH, editor. Structural equation modelling: concepts, issues, and applications. Thousand Oaks: SAGE; 1995. p. 56\u201375."},{"key":"506_CR38","volume-title":"Latent curve models: a structural equation perspective","author":"K Bollen","year":"2006","unstructured":"Bollen K, Curran P. Latent curve models: a structural equation perspective. Hoboken: Wiley; 2006."},{"key":"506_CR39","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2307\/2531734","volume":"44","author":"SL Zeger","year":"1988","unstructured":"Zeger SL, Liang K-Y, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049\u201360.","journal-title":"Biometrics."},{"key":"506_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1037\/1082-989X.3.4.424","volume":"3","author":"LT Hu","year":"1998","unstructured":"Hu LT, Bentler PM. Fit indices in covariance structure modelling: Sensitivity to under parameterized model misspecification. Psychol Methods. 1998;3:424.","journal-title":"Psychol Methods."},{"key":"506_CR41","doi-asserted-by":"publisher","first-page":"934162","DOI":"10.1155\/2015\/934162","volume":"2015","author":"S Ramaswamy","year":"2015","unstructured":"Ramaswamy S, Madabushi J, Hunziker J, Bhatia SC, Petty F. An open-label trial of memantine for cognitive impairment in patients with posttraumatic stress disorder. J Aging Res. 2015;2015:934162.","journal-title":"J Aging Res."},{"issue":"2","key":"506_CR42","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3233\/JAD-170424","volume":"60","author":"TMS Kishi","year":"2017","unstructured":"Kishi T MS, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer\u2019s disease: an updated systematic review and meta-analysis. J Alzheimers Dis. 2017;60(2):401\u201325.","journal-title":"J Alzheimers Dis."},{"issue":"1\u20132","key":"506_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jad.2011.09.040","volume":"136","author":"A Koukopoulos","year":"2012","unstructured":"Koukopoulos A, Serra G, Koukopoulos AE, Reginaldi D, Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial. J Affect Disord. 2012;136(1\u20132):163\u20136.","journal-title":"J Affect Disord."},{"key":"506_CR44","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/WNF.0b013e318184fae2","volume":"32","author":"PE Keck","year":"2009","unstructured":"Keck PE, Hsu HA, Papadakis K, Russo J. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation. Clin Neuropharmacol. 2009;32:199\u2013204.","journal-title":"Clin Neuropharmacol"},{"key":"506_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1399-5618.2011.00971.x","volume":"14","author":"A Anand","year":"2012","unstructured":"Anand A, Gunn AD, Barkay G, Karne HS, Nurnberger JI, Mathew SJ, Ghosh S. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord Bipolar Disord. 2012;14:64\u201370.","journal-title":"Bipolar Disord Bipolar Disord."},{"issue":"3","key":"506_CR46","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40262-013-0032-2","volume":"52","author":"M Noetzli","year":"2013","unstructured":"Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A, et al. Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet. 2013;52(3):211\u201323.","journal-title":"Clin Pharmacokinet."},{"key":"506_CR47","unstructured":"Forest Laboratories I. Memantine HCI (NDA 21-487) briefing document. Food and Drug Administration Peripheral and Central Nervous System Drugs Advisory Committee; 2003."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-018-0506-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0506-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0506-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:50:42Z","timestamp":1628617842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-018-0506-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["506"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0506-8","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"16 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors (Jayashri Kulkarni, Natalie Thomas, Abdul- Rahman Hudaib, Emorfia Gavrilidis, Jasmin Grigg, Raelene Tan, Jacinta Cheng, Amelia Arnold and Caroline Gurvich) have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"National Health and Medical and Research Council (NHMRC) Project Grant: 1129815 and Private Philanthropic Grant provided by Dr. Jeff Wolinski, C\/o Monash University Fundraising Department, Faculty of Medicine, Nursing and Health Sciences.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}